Great West Life Assurance Co. Can cut its position in Irhythm Technologies Inc (NASDAQ:IRTC) by 54.5% in the 3rd quarter, HoldingsChannel.com reports. The firm owned 1,420 shares of the company’s stock after selling 1,699 shares during the period. Great West Life Assurance Co. Can’s holdings in Irhythm Technologies were worth $105,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in IRTC. Amundi Pioneer Asset Management Inc. bought a new stake in Irhythm Technologies in the 1st quarter valued at $1,911,000. Cerebellum GP LLC bought a new stake in shares of Irhythm Technologies during the 2nd quarter valued at $348,000. SG Americas Securities LLC lifted its position in shares of Irhythm Technologies by 84.6% during the 2nd quarter. SG Americas Securities LLC now owns 33,696 shares of the company’s stock valued at $2,665,000 after acquiring an additional 15,439 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank lifted its position in shares of Irhythm Technologies by 93.5% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,825 shares of the company’s stock valued at $144,000 after acquiring an additional 882 shares during the period. Finally, Advisor Group Inc. lifted its position in shares of Irhythm Technologies by 403.1% during the 2nd quarter. Advisor Group Inc. now owns 805 shares of the company’s stock valued at $63,000 after acquiring an additional 645 shares during the period.

NASDAQ:IRTC opened at $68.56 on Friday. The stock has a fifty day moving average price of $70.31 and a 200-day moving average price of $74.19. The company has a current ratio of 2.66, a quick ratio of 2.59 and a debt-to-equity ratio of 2.53. Irhythm Technologies Inc has a fifty-two week low of $58.99 and a fifty-two week high of $98.13.

Irhythm Technologies (NASDAQ:IRTC) last released its earnings results on Tuesday, November 5th. The company reported ($0.74) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.40) by ($0.34). Irhythm Technologies had a negative net margin of 26.45% and a negative return on equity of 97.79%. The company had revenue of $55.96 million for the quarter, compared to the consensus estimate of $53.76 million. During the same quarter in the previous year, the company posted ($0.43) earnings per share. The business’s revenue was up 46.9% compared to the same quarter last year. Analysts expect that Irhythm Technologies Inc will post -1.54 earnings per share for the current year.

In other news, CFO Matthew C. Garrett sold 27,569 shares of the business’s stock in a transaction on Monday, August 12th. The stock was sold at an average price of $76.83, for a total transaction of $2,118,126.27. Following the completion of the transaction, the chief financial officer now owns 29,101 shares of the company’s stock, valued at approximately $2,235,829.83. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. 3.85% of the stock is currently owned by insiders.

A number of analysts have recently weighed in on IRTC shares. Zacks Investment Research upgraded Irhythm Technologies from a “hold” rating to a “buy” rating and set a $83.00 target price for the company in a research report on Wednesday, October 2nd. Oppenheimer started coverage on Irhythm Technologies in a research report on Tuesday, October 22nd. They set a “market perform” rating for the company. JPMorgan Chase & Co. upped their target price on Irhythm Technologies from $110.00 to $125.00 and gave the company an “overweight” rating in a research report on Thursday, August 1st. BTIG Research set a $90.00 target price on Irhythm Technologies and gave the company a “buy” rating in a research report on Wednesday, July 31st. Finally, BidaskClub upgraded Irhythm Technologies from a “strong sell” rating to a “sell” rating in a research report on Friday, October 18th. One research analyst has rated the stock with a sell rating, three have issued a hold rating and seven have assigned a buy rating to the company. The stock has a consensus rating of “Buy” and an average target price of $99.56.

Irhythm Technologies Company Profile

iRhythm Technologies, Inc, a digital healthcare company, provides ambulatory electrocardiogram (ECG) monitoring products for patients at risk for arrhythmias in the United States. The company offers Zio service, an ambulatory cardiac monitoring solution that combines a wire-free, patch-based, and wearable biosensor with a cloud-based data analytic platform to help physicians to monitor patients and diagnose arrhythmias.

Featured Article: Does a trade war provide a risk to the global economy?

Want to see what other hedge funds are holding IRTC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Irhythm Technologies Inc (NASDAQ:IRTC).

Institutional Ownership by Quarter for Irhythm Technologies (NASDAQ:IRTC)

Receive News & Ratings for Irhythm Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Irhythm Technologies and related companies with MarketBeat.com's FREE daily email newsletter.